Fexlamose

Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD) [1][2].

Product Specifications

CAS Number

[1285607-08-0]

Product Name Alternative

AER-01; MUC-031

UNSPSC

12352005

Target

Mucin

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Purity

99.93

Solubility

DMSO : 40 mg/mL (ultrasonic)

Smiles

SC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@@H]1O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CS

Molecular Formula

C12H22O9S2

Molecular Weight

374.43

References & Citations

[1]Vu SP, et al., Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions. Int J Mol Sci. 2025 Feb 28;26 (5) :2184.|[2]Addante A, et al. A. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. Eur Respir J. 2023 May 25;61 (5) :2202022.